As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The GASTRO Division of Hetero Healthcare is focused on providing therapeutic solutions for a broad range of gastrointestinal, digestive, and hepatobiliary health conditions. With digestive disorders ranging from common acid-related concerns to conditions requiring long-term management, the division aims to support healthcare professionals with dependable treatment options across the continuum of gastrointestinal care.
Its therapeutic portfolio addresses areas such as acidity and gastroesophageal reflux disease (GERD), peptic ulcer and acid-related disorders, functional gastrointestinal conditions, constipation, nausea and vomiting, digestive disturbances, and liver-related healthcare needs. Through targeted and supportive therapies, the division strives to address diverse digestive health concerns while supporting symptom management and overall gastrointestinal well-being.
Backed by Hetero Healthcare’s commitment to quality, accessibility, innovation, and patient-centric care, the GASTRO Division continues to strengthen its presence in digestive healthcare. With a focused approach to evolving clinical requirements, the division aims to support effective gastrointestinal disease management, enhance treatment experiences, and contribute to better patient outcomes.
View by-
